Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down before the market opened on Monday . The stock had previously closed at $52.6840, but opened at $49.0692. Zealand Pharma A/S shares last traded at $49.0692, with a volume of 100 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ZLDPF shares. Zacks Research cut shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday. Wolfe Research downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday. Finally, Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The stock has a market capitalization of $3.51 billion, a P/E ratio of 8.14 and a beta of 0.88. The business’s 50 day simple moving average is $45.69 and its two-hundred day simple moving average is $49.36. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.